Insights into synchronous peritoneal metastases from hepatobiliary origin : Incidence, risk factors, treatment, and survival from a nationwide database
Copyright © 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved..
INTRODUCTION: - This population-based study aimed to investigate incidence, risk factors, treatment, and survival of synchronous peritoneal metastases (PM) of hepatobiliary origin.
METHODS: - All Dutch patients diagnosed with hepatobiliary cancer between 2009 and 2018 were selected. Factors associated with PM were identified with logistic regression analyses. Treatments for patients with PM were categorized into local therapy, systemic therapy, and best supportive care (BSC). Overall survival (OS) was investigated using log-rank test.
RESULTS: - In total, 12 649 patients were diagnosed with hepatobiliary cancer of whom 8% (n = 1066) were diagnosed with synchronous PM (12% [n = 882/6519] in biliary tract cancer [BTC] vs. 4% [n = 184/5248] in hepatocellular carcinoma [HCC]). Factors that were positively associated with PM were the female sex (OR 1.18, 95% CI 1.03-1.35), BTC (OR 2.93, 95% CI 2.46-3.50), diagnosis in more recent years (2013-2015: OR 1.42, 95% CI 1.20-1.68; 2016-2018: OR 1.48, 95% CI 1.26-1.75), T3/T4 stage (OR 1.84, 95% CI 1.55-2.18), N1/N2 stage (OR 1.31, 95% CI 1.12-1.53) and other synchronous systemic metastases (OR 1.85, 95% CI 1.62-2.12). Of all PM patients, 723 (68%) received BSC only. Median OS was 2.7 months (IQR 0.9-8.2) in PM patients.
CONCLUSION: - Synchronous PM were found in 8% of all hepatobiliary cancer patients and occurred more often in BTC than in HCC. Most patients with PM received BSC only. Given the high incidence and dismal prognosis of PM patients, extended research in hepatobiliary PM is needed to achieve better outcome in these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 49(2023), 8 vom: 08. Aug., Seite 1436-1443 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rijken, Anouk [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biliary tract cancer |
|---|
| Anmerkungen: |
Date Completed 09.08.2023 Date Revised 15.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejso.2023.03.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354045741 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354045741 | ||
| 003 | DE-627 | ||
| 005 | 20231226061357.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejso.2023.03.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354045741 | ||
| 035 | |a (NLM)36898900 | ||
| 035 | |a (PII)S0748-7983(23)00175-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rijken, Anouk |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Insights into synchronous peritoneal metastases from hepatobiliary origin |b Incidence, risk factors, treatment, and survival from a nationwide database |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.08.2023 | ||
| 500 | |a Date Revised 15.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved. | ||
| 520 | |a INTRODUCTION: - This population-based study aimed to investigate incidence, risk factors, treatment, and survival of synchronous peritoneal metastases (PM) of hepatobiliary origin | ||
| 520 | |a METHODS: - All Dutch patients diagnosed with hepatobiliary cancer between 2009 and 2018 were selected. Factors associated with PM were identified with logistic regression analyses. Treatments for patients with PM were categorized into local therapy, systemic therapy, and best supportive care (BSC). Overall survival (OS) was investigated using log-rank test | ||
| 520 | |a RESULTS: - In total, 12 649 patients were diagnosed with hepatobiliary cancer of whom 8% (n = 1066) were diagnosed with synchronous PM (12% [n = 882/6519] in biliary tract cancer [BTC] vs. 4% [n = 184/5248] in hepatocellular carcinoma [HCC]). Factors that were positively associated with PM were the female sex (OR 1.18, 95% CI 1.03-1.35), BTC (OR 2.93, 95% CI 2.46-3.50), diagnosis in more recent years (2013-2015: OR 1.42, 95% CI 1.20-1.68; 2016-2018: OR 1.48, 95% CI 1.26-1.75), T3/T4 stage (OR 1.84, 95% CI 1.55-2.18), N1/N2 stage (OR 1.31, 95% CI 1.12-1.53) and other synchronous systemic metastases (OR 1.85, 95% CI 1.62-2.12). Of all PM patients, 723 (68%) received BSC only. Median OS was 2.7 months (IQR 0.9-8.2) in PM patients | ||
| 520 | |a CONCLUSION: - Synchronous PM were found in 8% of all hepatobiliary cancer patients and occurred more often in BTC than in HCC. Most patients with PM received BSC only. Given the high incidence and dismal prognosis of PM patients, extended research in hepatobiliary PM is needed to achieve better outcome in these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biliary tract cancer | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Incidence | |
| 650 | 4 | |a Peritoneal metastases | |
| 650 | 4 | |a Risk factors | |
| 650 | 4 | |a Survival | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Bakkers, Checca |e verfasserin |4 aut | |
| 700 | 1 | |a Klümpen, Heinz-Josef |e verfasserin |4 aut | |
| 700 | 1 | |a van der Geest, Lydia G |e verfasserin |4 aut | |
| 700 | 1 | |a de Vos-Geelen, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a van Erning, Felice N |e verfasserin |4 aut | |
| 700 | 1 | |a de Hingh, Ignace H J T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology |d 1993 |g 49(2023), 8 vom: 08. Aug., Seite 1436-1443 |w (DE-627)NLM01262862X |x 1532-2157 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:8 |g day:08 |g month:08 |g pages:1436-1443 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejso.2023.03.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 8 |b 08 |c 08 |h 1436-1443 | ||